ArticleFrontiers in oncology2025
Primary hepatic leiomyosarcoma concurrent with early-stage lung adenocarcinoma: a rare case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary hepatic leiomyosarcoma (PHL) is an extremely rare malignant mesenchymal tumor, accounting for less than 2% of all primary hepatic malignancies. We report a case of a 46-year-old female who presented with a one-year history of abdominal distension and pain. Imaging revealed a 6×5×4 cm mass in the left hepatic lobe (segments 3/4) and incidentally detected a suspicious pulmonary nodule. Laparoscopic partial left hepatectomy followed by thoracoscopic wedge resection of the left upper lung confirmed the diagnoses of primary hepatic leiomyosarcoma and primary lung adenocarcinoma (cT1aN0M0), respectively. This case highlights the importance of comprehensive diagnostics, immunohistochemical analysis, and multidisciplinary management of rare hepatic tumors, particularly when concurrent malignancies are present. This first reported case of concurrent PHL and primary lung adenocarcinoma provides valuable insights for clinical practice in managing patients with rare hepatic malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.